mobiflex and Spondylitis--Ankylosing

We concluded a randomized, controlled trial to compare once-daily 20 mg piroxicam versus once-daily 20 mg tenoxicam in ankylosing spondylitis. We recorded patients' dosing histories with electronic monitors for an average of 225 days (range 55-379) in 34 recipients of piroxicam and 31 recipients of tenoxicam. Dosing histories with the two agents were similar and are combined. Patients took 81% of prescribed doses; 78% once daily (as prescribed) and 3% as two or more daily doses. On 19% of all monitored days, there was no record of a dose being taken; 68% were single no-dose days, the rest (32%) being 2 to >10 consecutive no-dose days. In 3% of monitored days, extra doses were evidently taken, 88% as twice daily and 12% as three or more doses. Only 22% of all patients (14/65) strictly complied with the regimen: one dose daily every day. The remainder alternated between no-dose days and extra-dose days. We found no correlation between patient compliance and improvement in reported pain or morning stiffness.

Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Humans; Patient Compliance; Piroxicam; Spondylitis, Ankylosing; Time Factors; Treatment Outcome

To compare in a 3 month, multicenter, double blind, parallel study the efficacy and safety of a nonsteroidal antiinflammatory drug, aceclofenac, 100 mg bid orally, with that of tenoxicam, 20 mg orally at bedtime, in the treatment of adult patients with active ankylosing spondylitis (AS).. A total of 273 patients (135 in the aceclofenac group and 138 in the tenoxicam group) entered the study. Eight efficacy variables were assessed: morning stiffness, visual analog pain scale, control of additional paracetamol, modified Schöber's test, C7 line-iliac crest distance, lateral flexion of the spine, thoracic expansion, and occiput-wall distance.. Seven of the 8 variables improved significantly in both groups, with no differences between the 2 groups in any variable at the end of the study. Six percent of patients taking aceclofenac and 5% of patients taking tenoxicam withdrew because of unsatisfactory therapeutic action. Forty-two adverse events possibly or probably related to treatment were observed in the aceclofenac group and 37 in the tenoxicam group. However, only 2.2% of patients in the aceclofenac group and 1.4% in the tenoxicam group withdrew for this reason.. Aceclofenac and tenoxicam are similar in terms of safety and effectiveness; and aceclofenac, 100 mg orally twice daily, is a safe, effective, and convenient treatment for active AS.

Topics: Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Participation; Piroxicam; Placebos; Spondylitis, Ankylosing; Surveys and Questionnaires

A randomized study was performed on 24 patients with ankylosing spondylitis to compare the efficacy and tolerability of 20 mg tenoxicam daily with 50 mg diclofenac twice daily. There were 6 withdrawals from the group taking tenoxicam and 4 from the diclofenac group. Depression in 1 patient taking tenoxicam was the only significant adverse event. Both drugs were otherwise well tolerated. Tenoxicam and diclofenac were rated as good or excellent by 27% and 55% of patients, respectively. Global assessment, pain and duration of morning stiffness were improved with both drugs but this improvement was not statistically significant and there was no statistically significant difference between the two groups. This study confirms that tenoxicam is effective and well tolerated but larger numbers would be required to detect a small difference between groups.

Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Consumer Behavior; Diclofenac; Female; Humans; Male; Piroxicam; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing

Topics: Activities of Daily Living; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Piroxicam; Spondylitis, Ankylosing

Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Piroxicam; Random Allocation; Spondylitis, Ankylosing

Tenoxicam (20 mg/day) and piroxicam (20 mg/day) were compared in a double-blind, parallel group study over 4 weeks in 30 patients with ankylosing spondylitis. Both tenoxicam and piroxicam reduced spinal pain, but the improvement was greater with piroxicam. Tenoxicam and piroxicam were equally effective at improving duration of morning stiffness. Slight improvement was seen with other symptoms with both treatments. Patients were slightly more tolerant of piroxicam than tenoxicam and most patients elected to continue on their particular therapy at the end of the study.

Topics: Administration, Oral; Adult; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; Pain; Piroxicam; Random Allocation; Spondylitis, Ankylosing; Thiazines

A series of double-blind, parallel, clinical trials was carried out to assess the analgesic and anti-inflammatory effects of tenoxicam and to compare the efficacy and tolerance of this compound with those of piroxicam in patients suffering from osteoarthrosis, rheumatoid arthritis and ankylosing spondylitis. In equivalent once-daily dosage (20 mg), tenoxicam was found to be at least as effective as piroxicam in combating the symptoms of the above arthritic disorders and, even in relatively high dosages of 30 and 40 mg exhibited excellent tolerance, producing fewer adverse reactions than piroxicam. It is concluded that tenoxicam represents a valuable addition to the spectrum of anti-inflammatory agents.

Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Humans; Osteoarthritis; Piroxicam; Spondylitis, Ankylosing

Cases of half sister and brother with ankylosing spondylitis (AS) in whom drug therapy with salazosulfapyridine (SASP) showed excellent effect were reported. A 31 year-old female and her 28 year-old brother visited the out-patient clinic because of low back pain which lasted for the past 14 and 9 years, respectively. HLA examination revealed positive B27 antigen, X-ray and CT examination clarified sacroiliitis (grade III) in both patients. The diagnosis of AS was made and drug therapy with several non-steroidal anti-inflammatory drugs was started, but had little effects in both patients. After combination therapy with 2 g/day of SASP and 20 mg/day of tenoxicam, both clinical and laboratory abnormalities disappeared within a month. It is well known that AS has hereditary characteristic, nevertheless there were only a couple of case reports which showed familial occurrence of AS and there was no report showing the effectiveness of SASP for the drug therapy of AS in Japan. The patients reported here were the first cases with AS occurred in sister and brother in Japan. We emphasized SASP might be a drug which is useful for the treatment of AS.

Topics: Adult; Drug Therapy, Combination; Family Health; Female; Humans; Male; Piroxicam; Spondylitis, Ankylosing; Sulfasalazine